As a consequence of epidemiological studies showing significant associations of
vitamin D deficiency with a variety of adverse extra-skeletal clinical outcomes including
cardiovascular diseases,
cancer, and mortality, large
vitamin D randomized controlled trials (RCTs) have been designed and conducted over the last few years. The vast majority of these trials did not restrict their study populations to individuals with
vitamin D deficiency, and some even allowed moderate
vitamin D supplementation in the placebo groups. In these RCTs, there were no significant effects on the primary outcomes, including
cancer, cardiovascular events, and mortality, but explorative outcome analyses and meta-analyses revealed indications for potential benefits such as reductions in
cancer mortality or acute
respiratory infections. Importantly, data from RCTs with relatively high doses of
vitamin D supplementation did, by the vast majority, not show significant safety issues, except for trials in critically or severely ill patients or in those using very high intermittent
vitamin D doses. The recent large
vitamin D RCTs did not challenge the beneficial effects of
vitamin D regarding
rickets and
osteomalacia, that therefore continue to provide the scientific basis for nutritional
vitamin D guidelines and recommendations. There remains a great need to evaluate the effects of
vitamin D treatment in populations with
vitamin D deficiency or certain characteristics suggesting a high sensitivity to treatment. Outcomes and limitations of recently published large
vitamin D RCTs must inform the design of future
vitamin D or nutrition trials that should use more personalized approaches.